(Q40175453)

English

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial

scientific article published on 8 June 2017

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

phase III clinical trial

0 references

0 references

cystic fibrosis

0 references

1 reference

based on heuristic

inferred from title

Paul D. Robinson

object named as

Paul D Robinson

8

0 references

object named as

Felix Ratjen

1

0 references

author name string

Christopher Hug

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Gautham Marigowda

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Simon Tian

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Xiaohong Huang

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sanja Stanojevic

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Carlos E Milla

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

David Waltz

9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Jane C Davies

10

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

VX14-809-109 investigator group

11

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

publication date

8 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

557-567

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Aberrant CFTR-dependent HCO3- transport in mutations associated with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Year-to-year changes in lung function in individuals with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Detecting early structural lung damage in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of early subclinical lung disease in children with cystic fibrosis by lung ventilation imaging with hyperpolarised gas MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of Lung Clearance Index with Hyperpolarized 129Xe Magnetic Resonance Imaging in Pediatric Subjects with Cystic Fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung Clearance Index in Adults and Children With Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple-breath washout measurements can be significantly shortened in children

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Consensus statement for inert gas washout measurement using multiple- and single- breath tests.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lung clearance index: evidence for use in clinical trials in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Inert gas washout: theoretical background and clinical utility in respiratory disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Fecal elastase-1 cut-off levels in the assessment of exocrine pancreatic function in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2817%2930215-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(17)30215-1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40175453&oldid=2042140841"